Donor-derived cell-free DNA as a diagnostic marker for kidney-allograft rejection: A systematic review and meta-analysis
Biomolecules and Biomedicine · 20.02.2024 · 24 (4) · 731-740
DOI: 10.17305/bb.2024.10049 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 20.02.2024. Verfasst von Yanbo Xing und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China; Second Clinical Medical College, Shanxi Medical Univ…. Hauptthemen laut MEDLINE: Graft Rejection, Cell-Free Nucleic Acids, Kidney Transplantation, Biomarkers. Die Arbeit wurde bisher 25-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Donor-derived cell-free DNA (dd-cfDNA) has emerged as a promising biomarker for detecting graft rejection. This study aimed to evaluate the diagnostic accuracy and clinical value of applying it to kidney transplant rejection. Relevant literature on dd-cfDNA diagnostics in kidney transplant rejection was reviewed from PubMed, Embase, Cochrane Library, and Web of Science databases up to 2023. Data and study characteristics were extracted independently by two researchers, and disagreements were resolved through discussion. Diagnostic accuracy data for any rejection (AR) and antibody-mediated rejection (ABMR) were analyzed separately. Potential heterogeneity was analyzed by subgroup analysis or meta-regression. Funnel plots were used to clarify the presence or absence of publication bias. Nine publications provided data on dd-cfDNA accuracy in diagnosing patients with AR. The pooled sensitivity, specificity, and the area under the receiver operating characteristic (AUROC) curve with 95% confidence intervals (CI) were 0.59 (95% CI, 0.48-0.69), 0.83 (95% CI, 0.76-0.88), and 0.80 (95% CI, 0.76-0.83), respectively. Additionally, 12 studies focused on the diagnostic accuracy of dd-cfDNA for ABMR, showing pooled sensitivity, specificity, and the AUROC curve with 95% CI of 0.81 (95% CI, 0.72–0.88), 0.80 (95% CI, 0.73–0.86), and 0.87 (95% CI, 0.84-0.90), respectively. Study type, age group, and sample size contributed to heterogeneity. In summary, our findings indicate that while plasma dd-cfDNA accuracy in diagnosing patients with AR is limited by significant heterogeneity, it is a valuable biomarker for diagnosing ABMR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China; Second Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China.
- Department of Urology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Zitieren
APA
Xing, Y., Guo, Q., Wang, C., Shi, H., Zheng, J., Jia, Y., Li, C., & Hao, C. (2024). Donor-derived cell-free DNA as a diagnostic marker for kidney-allograft rejection: A systematic review and meta-analysis. Biomolecules and Biomedicine, 24(4), 731-740. https://doi.org/10.17305/bb.2024.10049
Vancouver
Xing Y, Guo Q, Wang C, Shi H, Zheng J, Jia Y, et al. Donor-derived cell-free DNA as a diagnostic marker for kidney-allograft rejection: A systematic review and meta-analysis. Biomolecules and Biomedicine. 2024;24(4):731-740. doi:10.17305/bb.2024.10049
BibTeX
@article{Xing2024,
author = {Xing, Yanbo and Guo, Qiang and Wang, Cong and Shi, Haoying and Zheng, Jiarui and Jia, Yijun and Li, Chengyong and Hao, Chuan},
title = {Donor-derived cell-free DNA as a diagnostic marker for kidney-allograft rejection: A systematic review and meta-analysis},
journal = {Biomolecules and Biomedicine},
year = {2024},
volume = {24},
number = {4},
pages = {731--740},
doi = {10.17305/bb.2024.10049}
}
EUVIMED